Allogene Therapeutics (ALLO) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.
- Allogene Therapeutics' Income towards Parent Company rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
- Allogene Therapeutics' Income towards Parent Company amounted to -$41.3 million in Q3 2025, which was up 18.82% from -$50.9 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Income towards Parent Company high stood at $1.9 million for Q4 2021, and its period low was -$97.0 million during Q1 2023.
- Its 3-year average for Income towards Parent Company is -$65.0 million, with a median of -$64.1 million in 2024.
- In the last 5 years, Allogene Therapeutics' Income towards Parent Company skyrocketed by 102.76% in 2021 and then crashed by 5,046.54% in 2022.
- Allogene Therapeutics' Income towards Parent Company (Quarterly) stood at $1.9 million in 2021, then tumbled by 5,046.54% to -$93.6 million in 2022, then rose by 15.80% to -$78.8 million in 2023, then grew by 27.02% to -$57.5 million in 2024, then soared by 36.60% to -$41.3 million in 2025.
- Its last three reported values are -$41.3 million in Q3 2025, -$50.9 million for Q2 2025, and -$59.8 million during Q1 2025.